Our skin is the primary victim of sun exposure, and as the summer sun grows harsher each year, protecting it becomes more ...

In a country where chronic skin diseases affect millions, one institution is rewriting the rulebook. Kayakalp Global, based ...

EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

Autoimmune pathology characterised by skin depigmentation, vitiligo is subject to many clichés. This dermatological disease is not psychosomatic, but the consequences it has on patients' lives cause a ...

Vitiligo is classified as an autoimmune disease affecting both adults and children of all genders, although more women and young females are prone to develop the condition. Nearly 50 percent of ...

If approved, Opzelura would provide an alternative to steroid drugs currently used to treat vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million ...

The vitiligo area scoring index (VASI ... Four previously released case studies - patients with skin type IV and varying disease duration - demonstrated repigmentation of vitiliginous lesions on the ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives,” published in the ...

There’s no shortage of pricey oils, gadgets, and OTC supplements promising to reverse shedding once it starts. But can you ...